GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC raised its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 1.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 387,400 shares of the company’s stock after buying an additional 7,329 shares during the period. Natixis Advisors LLC’s holdings in GE HealthCare Technologies were worth $30,288,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Cathy Pareto & Associates Inc. acquired a new position in GE HealthCare Technologies during the 4th quarter valued at about $670,000. LMR Partners LLP bought a new position in shares of GE HealthCare Technologies during the 3rd quarter valued at about $7,387,000. Principal Financial Group Inc. boosted its position in shares of GE HealthCare Technologies by 1.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,009,910 shares of the company’s stock valued at $94,780,000 after purchasing an additional 19,010 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of GE HealthCare Technologies during the 3rd quarter valued at about $1,396,000. Finally, Everence Capital Management Inc. boosted its position in shares of GE HealthCare Technologies by 118.2% during the 4th quarter. Everence Capital Management Inc. now owns 18,870 shares of the company’s stock valued at $1,475,000 after purchasing an additional 10,220 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price objective for the company from $95.00 to $103.00 in a research report on Wednesday, January 8th. The Goldman Sachs Group upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and raised their price objective for the company from $85.00 to $100.00 in a research report on Tuesday, March 11th. Wells Fargo & Company raised their price objective on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Finally, Citigroup lifted their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.75.

GE HealthCare Technologies Stock Performance

Shares of GEHC opened at $81.97 on Monday. The company’s 50 day moving average price is $87.26 and its 200 day moving average price is $86.13. GE HealthCare Technologies Inc. has a 52 week low of $74.51 and a 52 week high of $94.80. The company has a market capitalization of $37.48 billion, a PE ratio of 18.93, a PEG ratio of 3.19 and a beta of 1.13. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.83 and a current ratio of 1.04.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The firm had revenue of $5.32 billion for the quarter, compared to the consensus estimate of $5.33 billion. Research analysts expect that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.